Drug Search Results
More Filters [+]

BHV-1200

Alternative Names: bhv-1200, bhv 1200, bhv1200
Latest Update: 2021-02-22
Latest Update Note: Clinical Trial Update

Product Description

BHV-1200 is a Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19. (Sourced from: https://www.biohavenpharma.com/investors/news-events/press-releases/02-22-2021)

Mechanisms of Action: Viral Entry Reducer

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BHV-1200

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events